Evaluation of the Effectiveness of Direct-Acting Antiviral Agents in Patients With Hepatitis C

Ozturk-Cerik H., Esen S., ALTINTAŞ ÖNER B., Celik M., Ozdemir T., TANYEL E.

KLIMIK JOURNAL, cilt.33, sa.3, ss.297-306, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/kd.2020.60
  • Dergi Adı: KLIMIK JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.297-306
  • Anahtar Kelimeler: Hepatitis C, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, VIRUS GENOTYPE 1, 4 INFECTION, RIBAVIRIN, EFFICACY, LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR, SAFETY
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: Hepatitis C virus (HCV) infection is a global problem with personal, social and economic impacts. Approximately 85% of patients infected with HCV cannot achieve virus clearance. Cirrhosis, hepatocellular carcinoma and death may develop in patients with chronic infection.Until recently, treatments for chronic hepatitis C were difficult to use with many side effects, low treatment responses, and relapses. Direct-acting antivirals (DAAs) prevent HCV replication, and thir effectiveness is over 90%. In this study, we aimed to evaluate the achievement of these treatments.